Samwald research group
Emerging General-Purpose AI (GPAI) may dramatically accelerate biomedical research and the development of new treatments, offering huge potential for human health. These fast, possibly disruptive advances require that our guiding policies and practices adapt quickly. Our group develops essential policies to navigate the AI revolution in research, development, and practice. Through international collaborations, we address governance and ethical questions to ensure that as the capabilities of GPAI systems rapidly advance, we maximise their benefits while minimising associated systemic risks.
Samwald group
Lead: Matthias Samwald
Konstantin Hebenstreit